Drug Profile
Research programme: brain and psychiatric disorder therapeutics - Blue Oak Pharmaceuticals
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Blue Oak Pharmaceuticals
- Developer Blue Oak Pharmaceuticals; PsychoGenics
- Class
- Mechanism of Action Neuron modulators; Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain disorders; Psychiatric disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Brain-disorders in USA
- 28 Jan 2022 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 04 Dec 2017 Blue Oak Pharmaceuticals and Psychogenics enter into collaboration to develop therapeutics for Brain disorders and Psychiatric disorders